ONI

Executive Summary

ONI is a UK-based biotechnology company pioneering super-resolution microscopy with its integrated platform encompassing the Aplo Scope, Nanoimager, and Aplo Flow systems. Founded in 2016 and headquartered in Oxford, ONI simplifies access to advanced imaging techniques such as dSTORM, PALM, and DNA-PAINT, enabling researchers to visualize and quantify nanoscale biological processes. By embedding AI and machine learning into its hardware and software, ONI enhances data analysis, making high-resolution imaging more accessible and reproducible for life science research. The company targets the growing demand for precise molecular imaging in drug discovery, cell biology, and diagnostic development. ONI has established itself as a key innovator in the microscopy market, with its products already adopted by academic and pharmaceutical laboratories. While currently private, the company is well-positioned to capture market share as super-resolution imaging becomes a standard tool in research. Its focus on automation and AI-driven analytics differentiates it from traditional microscopy providers. ONI's growth trajectory suggests potential for scaling commercial operations and expanding into clinical applications, though its valuation and funding details remain undisclosed. The company's strategic partnerships and product development pipeline could drive near-term value.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Nanoimager with Enhanced AI Capabilities80% success
• Q4 2026Strategic Partnership with Major Pharma for Drug Discovery60% success
• Q2 2026Series B Funding Round to Accelerate Commercial Expansion70% success